Rapid Communication
Copyright ©2008 The WJG Press and Baishideng. All rights reserved.
World J Gastroenterol. Feb 21, 2008; 14(7): 1126-1132
Published online Feb 21, 2008. doi: 10.3748/wjg.14.1126
KAI1 is a potential target for anti-metastasis in pancreatic cancer cells
Jian-Hua Xu, Xiao-Zhong Guo, Li-Nan Ren, Li-Chun Shao, Min-Pei Liu
Jian-Hua Xu, Xiao-Zhong Guo, Li-Nan Ren, Li-Chun Shao, Min-Pei Liu, Department of Gastroenterology, The General Hospital of Shenyang Military Command, Shenyang 110016, Liaoning Province, China
Author contributions: Xu JH and Guo XZ contributed equally to this work; Xu JH, Guo XZ and Liu MP designed research; Xu JH, Ren LN and Shao LC performed research; Xu JH and Guo XZ analyzed data and wrote the paper.
Correspondence to: Dr. Xiao-Zhong Guo, Department of Gastroenterology, The General Hospital of Shenyang Military Command, No.83 Wenhua Road, Shenhe District, Shenyang 110016, Liaoning Province, China. guoxiaozhong1962@163.com
Telephone: +86-24-23056130
Fax: +86-24-23051113
Received: August 18, 2007
Revised: October 29, 2007
Published online: February 21, 2008
Abstract

AIM: To investigate whether KAI1, as a metastasis suppressor gene, is associated with invasive and metastatic ability of pancreatic cancer cells.

METHODS: KAI1 gene was transfected into pancreatic cancer cell line MiaPaCa II by liposomes selected with G418. Expression of transfected cells was measured by Western blotting, immunofluorescence and immunocytochemistry. Tumor cell invasion and metastatic ability were detected through gelatinase activity and reconstituted basement membrane (Matrigel) assay. pCMV-KAI1 was directly injected into the heterotopic human pancreatic adenocarcinoma successfully established in the groin of BALB/C nude mice, by subcutaneous injection of MiaPaCa II pancreatic cancer cells. The statistical analysis between groups was determined by Student’s two tailed t test.

RESULTS: By Western blotting, MiaPaCa II cells transfected by KAI1 gene indicated KAI1 expression at approximately 29.1 kDa. Cytoplasm staining was positive and uniformly spread in transfected cancer cells, using immunohistochemistry and immunofluorescence. The most obvious difference was present after 30 h (MiaPaca II 43.6 ± 9.42, pCMV-MiaPaca II 44.8 ± 8.56, pCMV-KAI1-MiaPaca II 22.0 ± 4.69, P < 0.05). Gelatinolysis revealed a wider and clearer band of gelatinolytic activity in non-transfected than in transfected cells (MiaPaCa II cells 30.8 ± 0.57, transfected cells 28.1 ± 0.65, P < 0.05). In vivo tumor growth rates of KAI1 transfectants with KAI1-Lipofectamine 1.22 ± 0.31 in A group were lower than control 4.61 ± 1.98 and pCMV-KAI 11.67 ± 0.81. Analyses of metastases with and without KAI1 transfection in mice were different in liver and lung between controls 1.62 ± 0.39, 0.45 ± 0.09, pCMV-KAI 1.01 ± 0.27, 0.33 ± 0.09 and KAI1-Lipofectamine 0.99 ± 0.21, 0.30 ± 0.09 respectively (P < 0.05).

CONCLUSION: High expression of KAI1 gene was found in transfected MiaPaCa II human pancreatic cancer cells with lower metastatic ability. KAI1 gene plays an important role in inhibiting metastasis of pancreatic cancer after direct injection into pancreatic adenocarcinoma. These results show that the suppressed invasion and motor function of pancreatic cancer cells may be a key reason why the KAI1 gene controls pancreatic cancer cell metastasis.

Keywords: KAI1; Pancreatic cancer cell line; Transfection; Immunocytochemistry; Western blotting; Immunofluorescence; Gelatinolysis